The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Correlation of stable disease (SD) as best response with survival outcomes in patients (pts) with clear cell (cc) metastatic renal cell carcinoma (mRCC) treated with high-dose interleukin-2 (HD IL-2).
Joseph Merriman
No relevant relationships to disclose
Kinjal Parikh
No relevant relationships to disclose
Srinivas Kiran Tantravahi
No relevant relationships to disclose
Alli M. Straubhar
No relevant relationships to disclose
Archana M. Agarwal
No relevant relationships to disclose
Arun Sendilnathan
No relevant relationships to disclose
Joan Van Atta
No relevant relationships to disclose
Julia A. Batten
No relevant relationships to disclose
Kenneth F. Grossmann
No relevant relationships to disclose
Wolfram E. Samlowski
No relevant relationships to disclose
David D. Stenehjem
No relevant relationships to disclose
Neeraj Agarwal
No relevant relationships to disclose